- Home
- DTI vs AGEN Comparison
DTI vs AGEN Comparison
Compare DTI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTI | AGEN |
|---|---|---|
| Founded | 1984 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.5M | 126.2M |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | DTI | AGEN |
|---|---|---|
| Price | $3.76 | $3.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 171.6K | ★ 372.3K |
| Earning Date | 06-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | ★ $154,446,000.00 | $42,877,086.00 |
| Revenue This Year | $1.36 | $5.19 |
| Revenue Next Year | $5.54 | $68.25 |
| P/E Ratio | ★ N/A | $8.04 |
| Revenue Growth | 1.59 | ★ 89.95 |
| 52 Week Low | $1.43 | $1.38 |
| 52 Week High | $4.38 | $7.34 |
Technical Indicators
Market Signals| Indicator | DTI | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.85 | 49.80 |
| Support Level | $2.09 | $2.90 |
| Resistance Level | $4.38 | $3.38 |
| Average True Range (ATR) | 0.28 | 0.18 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 53.85 | 52.69 |
Price Performance
Historical ComparisonAbout DTI Drilling Tools International Corporation
Drilling Tools International Corp manufactures, rents, inspects, and refurbishes downhole drilling tools primarily to companies in the oil and natural gas industry for bottom hole assemblies used in onshore and offshore horizontal and directional drilling. The company's United States operations have locations in Texas, California, Louisiana, Oklahoma, Pennsylvania, North Dakota, New Mexico, Utah, and Wyoming. The company's single segment derives revenues from customers by providing oilfield equipment and services to operators in the oil and natural gas sectors.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).